In 2018, sales of ESAs brands and biosimilars at the ex-manufacturer price level were almost $4.1 billion across the major markets (United States, EU5, and Japan). Throughout our 2018-2028 forecast period, biosimilars of Aranesp/Nesp (darbepoetin alfa) and Mircera (methoxy polyethylene glycol-epoetin beta) are expected to enter the major markets alongside currentlyavailable epoetin alfa biosimilars, further increasing the need for companies to set competitive pricing to either gain or maintainESA patient shares. We present our ESA forecasts for key reference brands and their biosimilars by therapeutic area, molecule, and region.

Table of contents

  • Nephrology
    • Market Forecast in the Major Pharmaceutical Markets
      • Terminology
    • Overarching Forecast Assumptions
      • Overview of ESA Brands in Forecast
        • Biosimilar Entry Assumptions for ESAs
      • Overview of Biosimilars ESA Assumptions
    • Drug-Specific Forecast Assumptions
      • Epogen, Procrit, Eprex, Espo
        • Forecast Assumptions
        • Market Forecast: Epogen / Espo
        • Market Forecast: Procrit / Eprex
        • Market Forecast: Short-Acting ESAs
      • Aranesp / Nesp
        • Forecast Assumptions
        • Market Forecast: Aranesp / Nesp
      • Mircera
        • Forecast Assumptions
        • Market Forecast: Mircera
        • Market Forecast: Long-Acting ESAs

Author(s): Hamzah Aideed, MSc

Hamzah Aideed is a Principal Analyst in the biosimilars team at Decision Resources Group. Hamzah’s responsibilities include conducting primary and secondary market research, generating key insights into biosimilars and the biopharmaceutical industry, and providing client support. His work in biosimilars encompasses four key therapy areas – immunology, oncology, endocrinology, and nephrology. Prior to joining DRG, Hamzah was a Senior Research Executive at Consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies, for bespoke ad-hoc consulting projects. He holds an in Biotechnology & Business Management from the University of Warwick and a in Biological Chemistry from Aston University.